MCID: OVR105
MIFTS: 37

Ovarian Serous Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Ovarian Serous Carcinoma

MalaCards integrated aliases for Ovarian Serous Carcinoma:

Name: Ovarian Serous Carcinoma 12 15 17
Ovarian Serous Adenocarcinoma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:0050933
UMLS 71 C1335177

Summaries for Ovarian Serous Carcinoma

Disease Ontology : 12 An ovarian carcinoma that has material basis in the lining of the ovary and produces a serum-like fluid.

MalaCards based summary : Ovarian Serous Carcinoma, also known as ovarian serous adenocarcinoma, is related to endometrial cancer and endometriosis. An important gene associated with Ovarian Serous Carcinoma is MIR21 (MicroRNA 21), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Letrozole and Hormone Antagonists have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and lymph node.

Related Diseases for Ovarian Serous Carcinoma

Diseases related to Ovarian Serous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 163)
# Related Disease Score Top Affiliating Genes
1 endometrial cancer 29.3 MIR200C MIR200B MIR200A MIR199A1 MIR145 MIR141
2 endometriosis 27.6 MIR99A MIR20A MIR200B MIR200A MIR199A1 MIR145
3 breast cancer 27.0 MIR27A MIR21 MIR20A MIR200C MIR200B MIR200A
4 ovarian cancer 25.8 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR214
5 pancreatic cancer 25.7 MIR99A MIR27A MIR23B MIR23A MIR214 MIR21
6 prostate cancer 24.2 MIRLET7B MIR99A MIR29A MIR27A MIR23B MIR23A
7 colorectal cancer 23.3 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
8 primary peritoneal carcinoma 11.8
9 polymyositis 10.4 MIR214 MIR21
10 ovarian epithelial cancer 10.4
11 benign mesothelioma 10.3
12 peritoneal mesothelioma 10.3
13 renal hypertension 10.3 MIR200B MIR200A MIR141
14 mesothelioma, malignant 10.2
15 cystadenoma 10.2
16 adenocarcinoma 10.2
17 ovarian serous cystadenocarcinoma 10.2
18 endometrial serous adenocarcinoma 10.2
19 papillary carcinoma 10.2
20 serous cystadenocarcinoma 10.2
21 carcinosarcoma 10.2
22 cervix carcinoma 10.1 MIR214 MIR200A MIR199A1 MIR141
23 retinal vascular disease 10.1 MIR21 MIR20A MIR199A1
24 aortic disease 10.1 MIR21 MIR199A1 MIR145
25 papillary adenocarcinoma 10.1
26 endometrioid ovary carcinoma 10.1
27 malignant peritoneal mesothelioma 10.1
28 esophagus adenocarcinoma 10.1 MIR21 MIR199A1 MIR145 MIR143
29 infratentorial cancer 10.1 MIR20A MIR199A1 MIR100
30 gallbladder disease 10.0 MIR199A1 MIR145 MIR143
31 bile duct adenocarcinoma 10.0 MIR21 MIR199A1 MIR145 MIR125A
32 bone inflammation disease 10.0 MIR21 MIR199A1 MIR125A
33 central nervous system cancer 10.0 MIR21 MIR199A1 MIR145 MIR125A
34 cervix small cell carcinoma 10.0 MIR199A1 MIR145 MIR143 MIR100
35 bone cancer 10.0 MIR21 MIR199A1 MIR145 MIR125A
36 lymphoma, hodgkin, classic 10.0 MIR21 MIR20A MIR200A
37 mature b-cell neoplasm 10.0 MIR23B MIR199A1 MIR125A
38 cerebral arterial disease 10.0 MIR199A1 MIR145 MIR143 MIR125A
39 melanoma, cutaneous malignant 1 9.9
40 pelvic organ prolapse 9.9
41 thyroid cancer, nonmedullary, 1 9.9
42 tuberous sclerosis 1 9.9
43 testicular germ cell tumor 9.9
44 wilms tumor 5 9.9
45 brittle bone disorder 9.9
46 mastitis 9.9
47 tuberous sclerosis 9.9
48 endodermal sinus tumor 9.9
49 papilloma 9.9
50 papillary serous adenocarcinoma 9.9

Graphical network of the top 20 diseases related to Ovarian Serous Carcinoma:



Diseases related to Ovarian Serous Carcinoma

Symptoms & Phenotypes for Ovarian Serous Carcinoma

Drugs & Therapeutics for Ovarian Serous Carcinoma

Drugs for Ovarian Serous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 19)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
2 Hormone Antagonists Phase 3
3 Estrogen Antagonists Phase 3
4 Hormones Phase 3
5 Estrogen Receptor Antagonists Phase 3
6 Estrogens Phase 3
7 Aromatase Inhibitors Phase 3
8
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
9
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
10
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 38904 498142
11 Immunologic Factors Phase 1, Phase 2
12 Anti-Infective Agents Phase 1, Phase 2
13 Antiviral Agents Phase 1, Phase 2
14 Immunosuppressive Agents Phase 1, Phase 2
15 Antimetabolites Phase 1, Phase 2
16 Albumin-Bound Paclitaxel Phase 1, Phase 2
17 Tubulin Modulators Phase 1, Phase 2
18 Antimitotic Agents Phase 1, Phase 2
19 BIRC5 protein, human

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum Recruiting NCT04095364 Phase 3 Carboplatin;Letrozole;Paclitaxel
2 A Pilot Phase II Trial of Radiation Therapy "Sandwiched" Between Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma Completed NCT00231868 Phase 2 Carboplatin and Paclitaxel and Pelvic Radiation Therapy;Carboplatin and Paclitaxel and Radiation Therapy
3 Phase 1 Dose Escalation and Expansion Cohort of Carboplatin and Gemcitabine With or Without M6620 (VX-970) in First or Second Recurrence Platinum-Sensitive Epithelial Ovarian, Peritoneal, and Fallopian Tube Cancer Recruiting NCT02627443 Phase 1, Phase 2 Berzosertib;Carboplatin;Gemcitabine;Gemcitabine Hydrochloride
4 A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin/Taxol Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma Not yet recruiting NCT04030000 Phase 1, Phase 2 Paclitaxel/Carboplatin
5 Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients Completed NCT02016833
6 Lavage of the Uterine Cavity for Diagnosis of Ovarian Carcinomas Recruiting NCT03606486

Search NIH Clinical Center for Ovarian Serous Carcinoma

Genetic Tests for Ovarian Serous Carcinoma

Anatomical Context for Ovarian Serous Carcinoma

MalaCards organs/tissues related to Ovarian Serous Carcinoma:

40
Ovary, Breast, Lymph Node, Liver, Kidney, Lung, Pancreas

Publications for Ovarian Serous Carcinoma

Articles related to Ovarian Serous Carcinoma:

(show top 50) (show all 440)
# Title Authors PMID Year
1
MicroRNA expression profiles in serous ovarian carcinoma. 46
18451233 2008
2
Bleeding and bowel obstruction in giant ovarian serous carcinoma - a video vignette. 61
31967392 2020
3
Pegylated Liposomal Doxorubicin/Oxaliplatin Chemotherapy Can Overcome Cisplatin Resistance in Spectrin αII-Overexpressing Ovarian Carcinoma. 61
32366394 2020
4
Tissue HE4 Expression Discriminates the Ovarian Serous Carcinoma but Not the Uterine Serous Carcinoma Patients. A New Adjunct to the Origin of the Tumor Site. 61
31165997 2020
5
Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma. 61
31876585 2020
6
Differential expression of immune related genes in high-grade ovarian serous carcinoma. 61
31918995 2020
7
Synchronous Cervical Adenocarcinoma and Ovarian Serous Adenocarcinoma-A Case Report and Literature Review. 61
32235322 2020
8
A novel c-Kit/phospho-prohibitin axis enhances ovarian cancer stemness and chemoresistance via Notch3-PBX1 and β-catenin-ABCG2 signaling. 61
32169072 2020
9
The "Far Left" of the Morphologic Spectrum of Ovarian High-Grade Serous Carcinoma: Case Report of a Purely Noninvasive High-Grade Serous Carcinoma Mimicking an Ovarian Serous Borderline Tumor. 61
32168063 2020
10
Multiplexed ion beam imaging (MIBI) for characterization of the tumor microenvironment across tumor types. 61
32203152 2020
11
Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding. 61
32098383 2020
12
Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. 61
32020965 2020
13
Surprise Lymph Node Histology in a Patient with Ovarian Serous Carcinoma. 61
32095299 2020
14
Mediastinal metastasis from ovarian serous carcinoma 29 years after initial treatment. 61
32257787 2020
15
Peritoneal Carcinomatosis From Yolk Sac Tumor in a Postmenopausal Woman Following Chemotherapy for High-grade Ovarian Serous Carcinoma. 61
30383611 2020
16
Compartment Syndrome of the Hand after Laparoscopic Gynecologic Surgery. 61
30936029 2020
17
Influence of marital status on overall survival in patients with ovarian serous carcinoma: finding from the surveillance epidemiology and end results (SEER) database. 61
31888704 2019
18
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma. 61
31771601 2019
19
CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress. 61
31766991 2019
20
An Unlikely Route: Metastatic Ovarian Malignancy within the Duodenum. 61
31768358 2019
21
Difficult Diagnosis of Peritoneal Serous Papillary Carcinoma in a 63-year-old Woman: A Case Report. 61
31448396 2019
22
A Shallow Convolutional Learning Network for Classification of Cancers Based on Copy Number Variations. 61
31569801 2019
23
A Comprehensive Review of Ovarian Serous Carcinoma. 61
31368906 2019
24
miRNA-301b-3p accelerates migration and invasion of high-grade ovarian serous tumor via targeting CPEB3/EGFR axis. 61
30834603 2019
25
Correction to: PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. 61
31337420 2019
26
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma. 61
31208449 2019
27
Maximal cytoreduction is related to improved disease-free survival in low-grade ovarian serous carcinoma. 61
30915911 2019
28
Metastatic Carcinoma of Endometrium from Primary Ovarian Serous Carcinoma Mimicking a Primary Uterine Tumour. 61
31133160 2019
29
Ovarian serous carcinoma in synthetic mesh: A rare case report and review of the literature. 61
30950130 2019
30
Metastasis of ovarian cancer to the bile duct: a case report. 61
31222668 2019
31
Stromal tumor-infiltrating lymphocytes evaluated on H&E-stained slides are an independent prognostic factor in epithelial ovarian cancer and ovarian serous carcinoma. 61
30944645 2019
32
Clinical Stratification of High-Grade Ovarian Serous Carcinoma Using a Panel of Six Biomarkers. 61
30857227 2019
33
Fallopian Tube Epithelial Changes in Ovarian Serous Tumors Compared with Control Group: A Single-Center Study. 61
31462842 2019
34
Characterization of malignant ovarian mass on [18F]FDG PET/CT: using metabolic indices and degree of solidity. 61
27050153 2019
35
Low Grade Ovarian Serous Carcinoma - A Clinical-Morphologic Study. 61
31297261 2019
36
CUEDC2 Contributes to Cisplatin-Based Chemotherapy Resistance in Ovarian Serious Carcinoma by Regulating p38 MAPK Signaling. 61
31205536 2019
37
Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer. 61
31681605 2019
38
[Peritoneal Cancer Resected as a Greater Omentum Mass-Report of a Patient Surviving Long Term without Recurrence]. 61
30692340 2018
39
Resection for Primary Retroperitoneal Serous Adenocarcinoma and Liver Metastasis. 61
30101904 2018
40
A study detection of the ROS1 gene fusion by FISH and ROS1 protein expression by IHC methods in patients with ovarian malignant or borderline serous tumors. 61
30249502 2018
41
A data science approach for the classification of low-grade and high-grade ovarian serous carcinomas. 61
30482155 2018
42
Architectural Histopathological Changes in Ovarian Serous Carcinomas. 61
31123612 2018
43
Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis. 61
30356023 2018
44
BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population. 61
30103829 2018
45
Expression of TLE-1 and CD99 in Carcinoma: Pitfalls in Diagnosis of Synovial Sarcoma. 61
27753659 2018
46
MicroRNA signatures discriminate between uterine and ovarian serous carcinomas. 61
29518404 2018
47
Expression of UCP2 is associated with sensitivity to platinum-based chemotherapy for ovarian serous carcinoma. 61
29928365 2018
48
Combination of serum CA19-9 and CA125 levels and contrast-enhanced ultrasound parametric data facilitates to differentiate ovarian serous carcinoma from ovarian malignant epithelial cancer. 61
29668586 2018
49
Decreased Eph receptor‑A1 expression is related to grade in ovarian serous carcinoma. 61
29393455 2018
50
Aldehyde dehydrogenase 1A1 (ALDH1A1) expression by immunohistochemistry is associated with chemo-refractoriness in patients with high-grade ovarian serous carcinoma. 61
28851663 2018

Variations for Ovarian Serous Carcinoma

Copy number variations for Ovarian Serous Carcinoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 109396 17 25800000 31800000 Deletion NF1 Ovarian serous carcinoma

Expression for Ovarian Serous Carcinoma

Search GEO for disease gene expression data for Ovarian Serous Carcinoma.

Pathways for Ovarian Serous Carcinoma

Pathways related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 12.09 MIRLET7B MIR99A MIR29A MIR27A MIR23B MIR23A
2 11.13 MIR93 MIR27A MIR23B MIR23A MIR145 MIR100
3 11.09 MIR200C MIR200B MIR200A MIR141
4 10.37 MIR199A1 MIR145

GO Terms for Ovarian Serous Carcinoma

Cellular components related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
2 extracellular vesicle GO:1903561 9.4 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B

Biological processes related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 MIRLET7B MIR27A MIR23B MIR23A MIR21
2 positive regulation of protein kinase B signaling GO:0051897 9.92 MIR29A MIR21 MIR199A1 MIR143
3 negative regulation of cell migration GO:0030336 9.91 MIR93 MIR29A MIR214 MIR21
4 negative regulation of gene expression GO:0010629 9.91 MIR93 MIR29A MIR27A MIR23B MIR214 MIR21
5 negative regulation of angiogenesis GO:0016525 9.87 MIR29A MIR214 MIR21 MIR200B MIR145 MIR143
6 negative regulation of inflammatory response GO:0050728 9.86 MIR20A MIR145 MIR141
7 positive regulation of angiogenesis GO:0045766 9.85 MIRLET7B MIR29A MIR21 MIR20A MIR199A1 MIR143
8 negative regulation of protein kinase B signaling GO:0051898 9.83 MIR29A MIR20A MIR200C MIR145
9 positive regulation of endothelial cell migration GO:0010595 9.81 MIR29A MIR21 MIR199A1
10 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.8 MIR27A MIR214 MIR21 MIR20A
11 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.79 MIR20A MIR200C MIR199A1
12 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.78 MIR27A MIR23B MIR23A MIR10B
13 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.76 MIR21 MIR20A MIR199A1 MIR145
14 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.74 MIR21 MIR20A MIR143
15 positive regulation of vascular endothelial cell proliferation GO:1905564 9.73 MIR29A MIR27A MIR21
16 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.73 MIR27A MIR23B MIR23A MIR20A
17 cell growth involved in cardiac muscle cell development GO:0061049 9.71 MIR23B MIR23A MIR199A1
18 negative regulation of vascular endothelial growth factor production GO:1904046 9.71 MIR93 MIR20A MIR199A1 MIR125A
19 negative regulation of cardiac muscle cell proliferation GO:0060044 9.69 MIR200B MIR199A1
20 positive regulation of cardiac muscle hypertrophy in response to stress GO:1903244 9.69 MIR214 MIR20A MIR199A1
21 negative regulation of vascular associated smooth muscle cell migration GO:1904753 9.68 MIR214 MIR21
22 negative regulation of interleukin-8 secretion GO:2000483 9.68 MIR93 MIR100
23 negative regulation of cardiac muscle hypertrophy GO:0010614 9.68 MIR21 MIR145
24 regulation of smooth muscle contraction GO:0006940 9.67 MIR145 MIR143
25 positive regulation of endothelial cell differentiation GO:0045603 9.67 MIR21 MIR200C
26 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.67 MIR27A MIR199A1
27 positive regulation of connective tissue replacement GO:1905205 9.66 MIR214 MIR199A1
28 negative regulation of interleukin-6-mediated signaling pathway GO:0070104 9.66 MIR99A MIR125A
29 negative regulation of cytokine-mediated signaling pathway GO:0001960 9.65 MIR21 MIR125A
30 negative regulation of leukocyte adhesion to vascular endothelial cell GO:1904995 9.65 MIR141 MIR125A
31 angiotensin-activated signaling pathway GO:0038166 9.65 MIR145 MIR143
32 negative regulation of STAT cascade GO:1904893 9.64 MIR99A MIR125A
33 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.64 MIR27A MIR21
34 negative regulation of receptor biosynthetic process GO:0010871 9.63 MIR23B MIR125A
35 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.63 MIRLET7B MIR27A MIR23B MIR23A MIR21 MIR10B
36 gene silencing by miRNA GO:0035195 9.62 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
37 aorta smooth muscle tissue morphogenesis GO:0060414 9.61 MIR145 MIR143
38 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.6 MIRLET7B MIR21
39 regulation of phenotypic switching GO:1900239 9.59 MIR145 MIR143
40 positive regulation of pulmonary blood vessel remodeling GO:1905111 9.58 MIR20A MIR143
41 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.58 MIR145 MIR143
42 miRNA mediated inhibition of translation GO:0035278 9.56 MIR29A MIR27A MIR21 MIR20A MIR200C MIR200B

Molecular functions related to Ovarian Serous Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.62 MIRLET7B MIR99A MIR93 MIR29A MIR27A MIR23B
2 mRNA 3'-UTR binding GO:0003730 9.43 MIR93 MIR21 MIR20A MIR200C MIR200B MIR125A
3 RNA polymerase II complex binding GO:0000993 9.33 MIR20A MIR145 MIR125A

Sources for Ovarian Serous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....